KALARIS THERAPEUTICS, INC. (KLRS) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$12.39M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$11.83M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$12.74M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$12.26M; Depreciation and amortization (m).
Complete source-backed ebitda history.
- Available history
- 2019-12-31 to 2023-12-31
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | (m) | -$12.39M | (m) | (m) | (m) | (m) | -$11.05M* | (m) | $9.02M | (m) | (m) |
|---|
| 2026-03-31 | Reported | (m) | -$11.83M | (m) | (m) | (m) | (m) | -$11.58M | (m) | $7.57M | (m) | (m) |
|---|
| 2025-09-30 | Reported | (m) | -$12.74M | (m) | (m) | (m) | (m) | -$11.33M* | (m) | $9.13M | (m) | (m) |
|---|
| 2025-06-30 | Reported | (m) | -$12.26M | (m) | (m) | (m) | (m) | -$12.54M* | (m) | $8.44M | (m) | (m) |
|---|
| 2025-03-31 | Reported | (m) | -$10.35M | (m) | (m) | (m) | (m) | -$7.44M | (m) | $6.03M | (m) | (m) |
|---|
| 2024-09-30 | Reported | (m) | -$37.85M | (m) | (m) | (m) | (m) | -$4.33M* | (m) | $36.02M | (m) | $0.00 |
|---|
| 2024-06-30 | Reported | (m) | -$4.19M | (m) | (m) | (m) | (m) | -$3.97M* | (m) | $3.21M | (m) | $0.00 |
|---|
| 2024-03-31 | Reported | (m) | -$2.56M | (m) | (m) | (m) | (m) | -$4.52M | (m) | $1.96M | (m) | $0.00 |
|---|
| 2023-12-31 | Reported | -$62.27M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2023-09-30 | Reported | -$46.88M* | -$46.96M | $86.00K* | (m) | (m) | (m) | -$34.48M* | (m) | $34.16M | (m) | $0.00 |
|---|
| 2023-06-30 | Reported | -$47.22M* | -$47.30M | $85.00K* | (m) | (m) | (m) | -$27.12M* | (m) | $34.82M | (m) | $0.00 |
|---|
| 2023-03-31 | Reported | -$43.15M | (m) | (m) | (m) | (m) | (m) | -$32.12M | (m) | $30.72M | (m) | $0.00 |
|---|
| 2022-12-31 | Reported | -$40.35M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2022-09-30 | Reported | -$42.87M* | -$42.95M | $85.00K* | (m) | (m) | (m) | -$35.13M* | (m) | $30.00M | (m) | $0.00 |
|---|
| 2022-06-30 | Reported | -$44.54M* | -$44.62M | $86.00K* | (m) | (m) | (m) | -$28.88M* | (m) | $31.38M | (m) | $150.00K |
|---|
| 2022-03-31 | Reported | -$42.73M | (m) | (m) | (m) | (m) | (m) | -$46.48M | (m) | $29.07M | (m) | $0.00 |
|---|
| 2021-12-31 | Reported | -$55.7M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2021-09-30 | Reported | -$45.46M* | -$45.50M | $44.00K* | (m) | (m) | $33.00K* | -$36.44M* | (m) | $33.06M | (m) | (m) |
|---|
| 2021-06-30 | Reported | -$37.62M* | -$37.66M | $33.00K* | (m) | (m) | $288.00K* | -$22.89M* | (m) | $25.68M | (m) | (m) |
|---|
| 2021-03-31 | Reported | -$30.85M | (m) | (m) | (m) | (m) | $75.00K | -$18.93M | (m) | $20.39M | (m) | $0.00 |
|---|
| 2020-12-31 | Reported | -$25.4M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2020-09-30 | Reported | -$23.88M* | -$23.90M | $18.00K* | (m) | (m) | (m) | -$18.06M* | (m) | $17.18M | (m) | (m) |
|---|
| 2020-06-30 | Reported | -$12.13M* | -$12.15M | $19.00K* | (m) | (m) | (m) | -$11.12M* | (m) | $8.88M | (m) | (m) |
|---|
| 2020-03-31 | Reported | -$9.82M | (m) | (m) | (m) | (m) | (m) | -$10.54M | (m) | $6.84M | (m) | (m) |
|---|
| 2019-09-30 | Reported | (m) | -$8.48M | (m) | $0.00* | (m) | -$7.00K* | -$6.40M* | (m) | $5.66M | (m) | (m) |
|---|
| 2019-06-30 | Reported | (m) | -$5.95M | (m) | (m) | (m) | (m) | (m) | (m) | $2.75M | (m) | (m) |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | (m) | -$46.15M | (m) | (m) | (m) | $200.00K | -$38.37M | (m) | $30.75M | (m) | $0.00 |
|---|
| 2024-12-31 | Reported | (m) | -$51.73M | (m) | (m) | (m) | (m) | -$20.67M | (m) | $45.04M | (m) | $0.00 |
|---|
| 2023-12-31 | Reported | -$199.5M | (m) | (m) | (m) | (m) | (m) | -$124.45M | (m) | $133.07M | (m) | -$126.00K |
|---|
| 2022-12-31 | Reported | -$170.48M | (m) | (m) | (m) | (m) | (m) | -$142.05M | (m) | $118.87M | (m) | -$265.00K |
|---|
| 2021-12-31 | Reported | -$169.63M | (m) | (m) | (m) | (m) | $26.00K | -$106.32M | (m) | $120.73M | (m) | $1.01M |
|---|
| 2020-12-31 | Reported | -$71.24M | (m) | (m) | (m) | (m) | $235.00K | -$60.81M | (m) | $49.66M | (m) | (m) |
|---|
| 2019-12-31 | Reported | -$26.68M | (m) | (m) | (m) | -16170.91% | $339.00K | -$20.16M | (m) | $16.25M | (m) | (m) |
|---|